Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis.
Immunisation of BALB/c mice with a vaccine containing Vi polysaccharide conjugated to the Klebsiella pneumoniae outer membrane 40 kDa protein (rP40), in combination with Escherichia coli heat-labile toxin adjuvant (LT), elicited anti-Vi IgG antibodies after administration using different routes. Testing of the immune serum in opsonisation assays demonstrated the specific enhancement of Vi-positive bacterial uptake by cultured murine bone marrow derived macrophages. Intra-peritoneal challenge of mice immunised with the Vi-based vaccine elicited a degree of protection against virulent Vi+ Salmonella enterica serovar typhimurium (S. typhimurium). In contrast, Vi vaccination did not confer protection against oral challenge with virulent Vi-positive S. typhimurium or S. dublin.
Hale
Christine
C
The Wellcome Trust Genome Campus, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK. cbh@sanger.ac.uk
Bowe
Frances
F
Pickard
Derek
D
Clare
Simon
S
Haeuw
Jean-Francois
JF
Powers
Ultan
U
Menager
Nathalie
N
Mastroeni
Pietro
P
Dougan
Gordon
G
D000818:Animals; D001428:Bacterial Vaccines / Q000276:immunology*; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D012480:Salmonella Infections / Q000276:immunology / Q000517:prevention & control*
D001428:Bacterial Vaccines; D011135:Polysaccharides, Bacterial; C054154:capsular polysaccharide, Salmonella